Brought to you by 
MDRNA grants nonexclusive RNA technology rights to Roche
02 Nov 2011
Executive Summary
In the first deal that validates its newly established RNAi drug discovery platform after switching focus from intranasal drug delivery, MDRNA (formerly Nastech) has granted Roche nonexclusive worldwide rights to its siRNA constructs and chemistry platform, which Roche will use to develop RNAi therapeutics.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MDRNA grants nonexclusive RNA technology rights to Roche
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice